vs

Side-by-side financial comparison of Liberty Broadband Corp (LBRDA) and MADRIGAL PHARMACEUTICALS, INC. (MDGL). Click either name above to swap in a different company.

MADRIGAL PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($321.1M vs $261.0M, roughly 1.2× Liberty Broadband Corp). Liberty Broadband Corp runs the higher net margin — 146.7% vs -18.2%, a 165.0% gap on every dollar of revenue. On growth, MADRIGAL PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (210.8% vs 6.1%). Liberty Broadband Corp produced more free cash flow last quarter ($37.0M vs $-133.8M).

Liberty Global Ltd. is a British-Dutch-American multinational telecommunications company domiciled in Bermuda, with headquarters in London, Amsterdam and Denver. Its respective legal names are Liberty Global Holdings Limited (UK), Liberty Global B.V. (Netherlands) and Liberty Global, Inc., with the first of these being publicly traded. It was formed in 2005 by the merger of the international arm of Liberty Media and UnitedGlobalCom (UGC).

Intercept Pharmaceuticals, Inc. is an American biopharmaceutical company incorporated in 2002, focusing on the development of novel synthetic bile acid analogs to treat chronic liver diseases, such as primary biliary cirrhosis (PBC) now called primary biliary cholangitis, non-alcoholic fatty liver disease, cirrhosis, portal hypertension, primary sclerosing cholangitis and also the intestinal disorder, bile acid diarrhea.

LBRDA vs MDGL — Head-to-Head

Bigger by revenue
MDGL
MDGL
1.2× larger
MDGL
$321.1M
$261.0M
LBRDA
Growing faster (revenue YoY)
MDGL
MDGL
+204.7% gap
MDGL
210.8%
6.1%
LBRDA
Higher net margin
LBRDA
LBRDA
165.0% more per $
LBRDA
146.7%
-18.2%
MDGL
More free cash flow
LBRDA
LBRDA
$170.8M more FCF
LBRDA
$37.0M
$-133.8M
MDGL

Income Statement — Q2 FY2025 vs Q4 FY2025

Metric
LBRDA
LBRDA
MDGL
MDGL
Revenue
$261.0M
$321.1M
Net Profit
$383.0M
$-58.6M
Gross Margin
Operating Margin
15.7%
-18.6%
Net Margin
146.7%
-18.2%
Revenue YoY
6.1%
210.8%
Net Profit YoY
96.4%
1.4%
EPS (diluted)
$2.68
$-2.55

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LBRDA
LBRDA
MDGL
MDGL
Q4 25
$321.1M
Q3 25
$287.3M
Q2 25
$261.0M
$212.8M
Q1 25
$266.0M
$137.3M
Q4 24
$263.0M
$103.3M
Q3 24
$262.0M
$62.2M
Q2 24
$246.0M
Q1 24
$245.0M
$0
Net Profit
LBRDA
LBRDA
MDGL
MDGL
Q4 25
$-58.6M
Q3 25
$-114.2M
Q2 25
$383.0M
$-42.3M
Q1 25
$268.0M
$-73.2M
Q4 24
$291.0M
$-59.4M
Q3 24
$142.0M
$-107.0M
Q2 24
$195.0M
Q1 24
$241.0M
$-147.5M
Gross Margin
LBRDA
LBRDA
MDGL
MDGL
Q4 25
Q3 25
Q2 25
Q1 25
96.7%
Q4 24
Q3 24
Q2 24
Q1 24
Operating Margin
LBRDA
LBRDA
MDGL
MDGL
Q4 25
-18.6%
Q3 25
-39.7%
Q2 25
15.7%
-22.2%
Q1 25
16.2%
-57.8%
Q4 24
4.9%
-64.8%
Q3 24
11.5%
-187.1%
Q2 24
8.5%
Q1 24
11.4%
Net Margin
LBRDA
LBRDA
MDGL
MDGL
Q4 25
-18.2%
Q3 25
-39.8%
Q2 25
146.7%
-19.9%
Q1 25
100.8%
-53.4%
Q4 24
110.6%
-57.5%
Q3 24
54.2%
-172.0%
Q2 24
79.3%
Q1 24
98.4%
EPS (diluted)
LBRDA
LBRDA
MDGL
MDGL
Q4 25
$-2.55
Q3 25
$-5.08
Q2 25
$2.68
$-1.90
Q1 25
$1.87
$-3.32
Q4 24
$2.04
$-2.50
Q3 24
$0.99
$-4.92
Q2 24
$1.36
Q1 24
$1.69
$-7.38

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LBRDA
LBRDA
MDGL
MDGL
Cash + ST InvestmentsLiquidity on hand
$180.0M
$198.7M
Total DebtLower is stronger
$3.1B
$339.9M
Stockholders' EquityBook value
$10.4B
$602.7M
Total Assets
$16.6B
$1.3B
Debt / EquityLower = less leverage
0.30×
0.56×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LBRDA
LBRDA
MDGL
MDGL
Q4 25
$198.7M
Q3 25
$295.7M
Q2 25
$180.0M
$186.2M
Q1 25
$226.0M
$183.6M
Q4 24
$163.0M
$100.0M
Q3 24
$168.0M
$232.7M
Q2 24
$73.0M
Q1 24
$108.0M
$622.5M
Total Debt
LBRDA
LBRDA
MDGL
MDGL
Q4 25
$339.9M
Q3 25
$339.8M
Q2 25
$3.1B
$118.4M
Q1 25
$3.8B
$118.0M
Q4 24
$3.8B
$117.6M
Q3 24
$3.7B
$117.1M
Q2 24
$3.6B
Q1 24
$3.6B
$116.1M
Stockholders' Equity
LBRDA
LBRDA
MDGL
MDGL
Q4 25
$602.7M
Q3 25
$625.7M
Q2 25
$10.4B
$696.0M
Q1 25
$10.1B
$710.6M
Q4 24
$9.8B
$754.4M
Q3 24
$9.5B
$777.2M
Q2 24
$9.3B
Q1 24
$9.1B
$850.8M
Total Assets
LBRDA
LBRDA
MDGL
MDGL
Q4 25
$1.3B
Q3 25
$1.4B
Q2 25
$16.6B
$1.0B
Q1 25
$17.0B
$996.6M
Q4 24
$16.7B
$1.0B
Q3 24
$16.3B
$1.1B
Q2 24
$16.0B
Q1 24
$15.7B
$1.1B
Debt / Equity
LBRDA
LBRDA
MDGL
MDGL
Q4 25
0.56×
Q3 25
0.54×
Q2 25
0.30×
0.17×
Q1 25
0.38×
0.17×
Q4 24
0.38×
0.16×
Q3 24
0.39×
0.15×
Q2 24
0.39×
Q1 24
0.40×
0.14×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LBRDA
LBRDA
MDGL
MDGL
Operating Cash FlowLast quarter
$91.0M
$-133.5M
Free Cash FlowOCF − Capex
$37.0M
$-133.8M
FCF MarginFCF / Revenue
14.2%
-41.7%
Capex IntensityCapex / Revenue
20.7%
0.1%
Cash ConversionOCF / Net Profit
0.24×
TTM Free Cash FlowTrailing 4 quarters
$-49.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LBRDA
LBRDA
MDGL
MDGL
Q4 25
$-133.5M
Q3 25
$79.8M
Q2 25
$91.0M
$-47.1M
Q1 25
$78.0M
$-88.9M
Q4 24
$1.0M
$-104.5M
Q3 24
$24.0M
$-67.0M
Q2 24
$27.0M
Q1 24
$52.0M
$-149.2M
Free Cash Flow
LBRDA
LBRDA
MDGL
MDGL
Q4 25
$-133.8M
Q3 25
$79.0M
Q2 25
$37.0M
Q1 25
$13.0M
Q4 24
$-63.0M
$-104.7M
Q3 24
$-36.0M
$-67.8M
Q2 24
$-35.0M
Q1 24
$-9.0M
$-149.5M
FCF Margin
LBRDA
LBRDA
MDGL
MDGL
Q4 25
-41.7%
Q3 25
27.5%
Q2 25
14.2%
Q1 25
4.9%
Q4 24
-24.0%
-101.3%
Q3 24
-13.7%
-109.0%
Q2 24
-14.2%
Q1 24
-3.7%
Capex Intensity
LBRDA
LBRDA
MDGL
MDGL
Q4 25
0.1%
Q3 25
0.3%
Q2 25
20.7%
0.0%
Q1 25
24.4%
0.0%
Q4 24
24.3%
0.2%
Q3 24
22.9%
1.3%
Q2 24
25.2%
Q1 24
24.9%
Cash Conversion
LBRDA
LBRDA
MDGL
MDGL
Q4 25
Q3 25
Q2 25
0.24×
Q1 25
0.29×
Q4 24
0.00×
Q3 24
0.17×
Q2 24
0.14×
Q1 24
0.22×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

LBRDA
LBRDA

Segment breakdown not available.

MDGL
MDGL

Rebates Customer Fees Credits Co Pay Assistance And Other$208.5M65%
Other$76.0M24%
Chargebacks Discounts For Prompt Pay And Other Allowances$36.6M11%

Related Comparisons